Patient Satisfaction with Calcipotriol/Betamethasone Dipropionate Cream in Psoriatic Patients Previously Treated With Foam Vehicle.

Introduction: Topical therapy is the first-line treatment for mild-to-moderate psoriasis, and guidelines recommend the combination of calcipotriene and betamethasone dipropionate (Cal/BD) as the preferred option, with its wide range of available formulations.

Objectives: The aims of this study were to assess the preference for Cal/BD cream in a group of patients previously treated with Cal/BD foam spray and to evaluate their satisfaction with the treatment.

Method: We conducted a prospective observational study on psoriatic patients treated with Cal/BD cream who had used Cal/BD foam in the previous three months. After four weeks of treatment, the comparison between the cream and the previous treatment with the foam was evaluated by a Patient Preference Questionnaire (PPQ). Additionally, patient satisfaction was evaluated through Psoriasis Treatment Convenience Scale (PTCS) and the Topical Therapy Adherence Questionnaire (TTAQ).

Results: Thirty patients with mild-to-moderate psoriasis were enrolled. After 28 days of treatment, PASI, BSA, and DLQI scores showed significant improvement (P<0.03). According to the Patient Preference Questionnaire (PPQ), 24/30 patients found Cal/BD cream overall preferable to the Cal/BD foam formulation. Moreover, PTCS and TTAQ questionnaires found a very high level of satisfaction with the cream.

Conclusion: These findings suggest that Cal/BD cream represents a valuable therapeutic option for patients starting topical treatment thanks to its high cosmetic acceptability.